<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174795</url>
  </required_header>
  <id_info>
    <org_study_id>NP39596</org_study_id>
    <secondary_id>2016-004478-16</secondary_id>
    <nct_id>NCT03174795</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection</brief_title>
  <official_title>A Non-Randomized, Open-Label, One Treatment, One Group Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Patients With a Complicated Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, open-label, one-treatment, one group study in participants with
      complicated urinary tract infection (cUTI) including pyelonephritis to characterize the
      pharmacokinetics of RO7079901 co-administered with meropenem.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Actual">December 16, 2017</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUC0-tau) of RO7079901</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Clearance (CL) of RO7079901</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of RO7079901</measure>
    <time_frame>Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of RO7079901</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Amount Excreted in Urine Over the Dosing Interval (Ae) of RO7079901</measure>
    <time_frame>Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction Excreted into the Urine (Fe) of RO7079901</measure>
    <time_frame>Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) of RO7079901</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State Volume of Distribution (Vss) of RO7079901</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tau of Meropenem</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of Meropenem</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr of Meropenem</measure>
    <time_frame>Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Meropenem</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae of Meropenem</measure>
    <time_frame>Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fe of Meropenem</measure>
    <time_frame>Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Meropenem</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of Meropenem</measure>
    <time_frame>Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>RO7079901 and Meropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7079901</intervention_name>
    <description>Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.</description>
    <arm_group_label>RO7079901 and Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.</description>
    <arm_group_label>RO7079901 and Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requiring hospitalization for IV antibacterial therapy for the treatment of
             presumed/confirmed cUTI (including pyelonephritis)

          -  Clinical signs and/or symptoms of pyelonephritis or a cUTI

          -  Urine culture taken within the 48 hours (hr) period immediately preceding the first
             dose of study drug contains greater than (&gt;)1x10^5 colony forming units (CFU) per
             milliliter (CFU/mL) of a gram negative organism

          -  Negative urine pregnancy test result confirmed by a blood test

          -  Agreement to remain abstinent or use a contraceptive method

        Exclusion Criteria:

          -  Has a concomitant infection requiring antibacterial therapy, in addition to study drug

          -  Confirmed fungal urinary tract infection

          -  Moderate or severe renal impairment, or end-stage renal disease requiring renal
             replacement therapy or a recipient of a renal transplant

          -  Documented presence of immunodeficiency, or a severely immunocompromised condition or
             use of systemic immunosuppressant therapy

          -  Any rapidly progressing disease or immediately life-threatening illness, or other
             terminal illness or condition with high risk of mortality meaning that the participant
             is considered, in the opinion of the Investigator, unlikely to survive the study
             period

          -  Urinary tract surgery or clinically significant urogenital trauma in the one week
             immediately preceding study entry

          -  Urinary tract infection (UTI) symptoms potentially attributable to another process
             (sexually transmitted infections or prostatitis)

          -  Suspected or confirmed perinephric or intra renal abscess

          -  Complete obstruction of any portion of the urinary tract, or a permanent urinary
             diversion

          -  History of epilepsy, brain lesions or other significant neurological disorders

          -  Use of probenecid within the 7 days before enrollment

          -  Known history of clinically significant hypersensitivity or severe allergic reaction
             to meropenem or any other antibiotic

          -  Any other ongoing condition or disease, or clinically significant abnormalities in
             laboratory test results that the investigator considers would render the participant
             unsuitable for the study

          -  Women who are pregnant, planning to become pregnant, or lactating

          -  Participation in a clinical study of an investigational drug or device within one
             month prior to enrollment

          -  Prior enrollment in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center For Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, First Dept of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Imre Egyetemi Oktatokorhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Korhaz-Rend. Eges. Szol.; Klinikai Farm. Infek. es Allerg. Intezet</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional hospital</name>
      <address>
        <city>Liepaja</city>
        <zip>3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.Stradina Kliniska Uni Tes Slimnica; Latvian Center of Nephrology</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East clinical university hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Urologii Ogólnej: Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu; Urology</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Dzieciątka Jezus; Oddział Urologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia; Clinic of Urology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

